Merck & Co., Inc. (MRK) Financials

Merck & Co., Inc. (NYSE: MRK) had a very weak start to 2026 on the income statement, with Q1 2026 revenue essentially flat year over year but profitability turning sharply negative. Revenue came in at $16.29 billion versus $15.53 billion in Q1 2025, yet the company posted an operating loss of $3.40 billion and a net loss of $4.24 billion, or -$1.72 per share. That compares with $5.09 billion of net income in the prior-year quarter.

The main issue was expense pressure. R&D expense surged to $12.59 billion in Q1 2026, far above the $3.62 billion level in Q1 2025, while total operating expenses rose to $15.49 billion. As a result, Merck’s gross profit of $12.09 billion was not enough to cover costs. This is the biggest red flag in the quarter and suggests a major earnings headwind, whether from pipeline spending, acquisition-related items, or unusual charges.

Cash flow was better than earnings. Merck generated $3.92 billion of operating cash flow in Q1 2026, which shows the core business still produced cash even in a loss quarter. However, investing and financing uses were heavy: the company spent $10.21 billion on investing activities and $2.98 billion on financing activities, leading to a $9.29 billion decline in cash and equivalents during the quarter.

The balance sheet remains sizable, but leverage is worth watching. As of March 31, 2026, Merck held $5.33 billion in cash and equivalents and $375 million in short-term investments, against $82.75 billion in total liabilities and $45.88 billion in common equity. Long-term debt stood at $46.67 billion, up from $33.97 billion at the end of Q2 2025 and $33.68 billion at year-end 2024. That increase in debt is notable even though the company still has substantial asset coverage.

Looking at the last several quarters, Merck’s earnings profile has been volatile. In 2025, the company posted strong quarters in Q2 and Q3, with quarterly net income of $4.43 billion and $5.79 billion, respectively. But Q4 2025 fell back to $2.96 billion, and Q1 2026 swung to a loss. This points to a business that can still produce strong profits, but with results that may be highly uneven.

Here are the most important takeaways for investors:

• Revenue growth held up in Q1 2026, rising to $16.29 billion from $15.53 billion a year ago.
• Operating cash flow remained positive at $3.92 billion, showing the underlying business still generates cash.
• Merck continues to return capital to shareholders, with dividends of $0.85 per share in Q1 2026.
• Prior 2025 quarters showed strong profit power, including Q3 2025 net income of $5.79 billion and Q2 2025 net income of $4.43 billion.
• Quarterly results remain volatile, making it harder to judge the company on a single period.
• The balance sheet is still large and asset-rich, with $128.69 billion in total assets.
• Goodwill and intangible assets remain significant, which is common for pharma but can add risk if acquisitions underperform.
• Q1 2026 operating income turned sharply negative at a $3.40 billion loss.
• R&D spending jumped dramatically to $12.59 billion, weighing heavily on earnings.
• Debt increased materially, with long-term debt rising to $46.67 billion.

Bottom line: Merck still looks like a company with meaningful scale and cash generation, but Q1 2026 was a clear earnings setback. Investors should watch whether the spike in R&D and the recent debt increase are temporary, acquisition-related, or the start of a tougher profit cycle. The stock’s longer-term case likely depends on whether Merck can convert its strong revenue base back into consistent operating leverage.